PolymarketVérifier la disponibilitéSans KYCDonnées de résolution vérifiéesBien calibréProbabilité implicite actuelle
December 31, 67%En tête parmi 3 options
December 31, 67%Qualité du marché
63 / 100
Qualité moyenneVolume 24h
276 €
Liquidité
19,2 k €
Liquidité moyenneÉcart
1.0 pt
Spread serréCommentaires
0
Données du marché
Mis à jour il y a 14 minutes
19 août 26, 17:49 UTC1 janv. 28, 04:59 UTC
Tendances
Conditions de la plateforme
Source : Polymarket
Ces conditions sont indicatives ; les opérations simulées de CoinRithm suivent leurs propres règles.
- Ordre minimum (parts):
- 5
- Pas de cotation:
- 1 points de pourcentage
- Frais:
- Oui
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Is Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketWill the Russian cancer vaccine work?
Manifold MarketsFDA approves Retatrutide this year?
PolymarketFDA approves YCT-529 male birth control pill before 2035?
Manifold MarketsRègles
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
